Physician profile
Perminder Grewal
NPI 1053381715
$18,996.13
in general payments reported to CMS, 2019-2025
11 companies · $602 in 2025
The $602 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $251 · 2021: $1,121 · 2022: $482 · 2023: $1,368 · 2024: $398 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,368.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $12,599.41 | 2019 | |
| Boston Scientific Corporation | $4,690.82 | 2019-2025 | General - Therapies, Watchman Access System, Resonate El Icd Vr |
| Astrazeneca Pharmaceuticals Lp | $485.40 | 2019-2021 | |
| Stryker Corporation | $485.34 | 2023-2024 | Mako |
| Impulse Dynamics (USA) INC. | $223.08 | 2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $200.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $125.01 | 2022 | |
| Amarin Pharma, INC. | $124.97 | 2019 | |
| Cvrx, INC. | $31.25 | 2024 | Barostim Neo System |
| Edwards Lifesciences Corporation | $16.81 | 2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $14.04 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perminder Grewal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.